Targeting Driver Mutations in mNSCLC: Impact of 2019 ASCO Meeting on Clinical Practice

Introduction

OBR and MDoutlook are pleased to share more excerpts from the most recent MDoutlook OncoPolls™ following this year’s ASCO annual meeting in Chicago. This report highlights four (4) oral presentations concerning new targeted agents being developed against recognized driver mutations in metastatic non-small cell lung cancer (mNSCLC). These agents are: Capmatinib and Tepotinib (both targeting MET with exon 14 mutations), TAK-788 (targets specific EGFR mutations with exon 20 insertions), and BLU-667 (RET inhibitor).

This research is based on separate, identical surveys conducted with US and EU5-based treaters of mNSCLC. The full complimentary report is available through MDoutlook per details below.

OncoPoll™ Methodology

  • Primary research surveys were sent to verified and validated oncologists with an identified clinical interest in lung cancers utilizing targeting parameters within the proprietary MDoutlook®global cancer treater panel
  • Timing: June 2019. Launched shortly after close of 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago, IL., May 31-June 4, 2019
  • Fielding via interactive web-based survey instruments, utilizing proven MDoutlook methodology and proprietary technology
  • Links to discussed abstracts on the ASCO website were provided within the survey
  • Responses: 101 total, 50 oncologists in US and 51 oncologists EU5

Current Awareness and Evaluation of New Targeted Agents in mNSCLC

Key Conclusions around New Targeted Agents for mNSCLC

  • Overall level of awareness about each of these agents is already moderate, even though all presentations were relatively early Ph1 – Ph2 trials
    • Roughly 25-40% of respondents had no awareness about each of these agents [links to Abstracts were provided after measuring awareness so evaluation could be done by all]
    • Europeans are more aware of these agents than American oncologists, even though attendance at the mNSCLC Oral abstract session was similar (see full report for details)
  • After reviewing the abstract, the respondents believe all of these agents have a better efficacy potential and safety profile than currently available options for these relevant patient subgroups
    • Fewer than 3% think any of these agents have a worse efficacy profile than currently available options, while 7% believe any’s side effects are worse than currently available treatments
    • Overall, the ratings are very consistent between US and EU5 oncologists

Comparison of New Targeted Agents for mNSCLC

Key Conclusions about Comparison of New Targeted Agents for mNSCLC

  • We asked the respondents to rank the 4 agents as to their likely greatest impact on their NSCLC practices
  • Each of these 4 drugs had their fans (selected most important) and detractors (selected least important)
  • US and EU5 oncologists are divided on which agents will have biggest impact on their practices
    • US #1 ranking (Tepotinib) is driven by having the most oncologists rank it as the most important, while the #1 in EU5 (Capmatinib) is driven by having fewest rank it as least impactful (and over 50% ranking it their #2)
  • Directly comparing the rankings for the 2 MET inhibitors, Tepotinib has more fans in both the US and EU5, but it also has more detractors than Capmatinib
    • Overall, US ranks Tepotinib higher while EU5 oncologists rank Capmatinib better

Overall Conclusions: Impact of 2019 ASCO Annual Meeting on Clinical Practice for mNSCLC with Driver Mutations

  • A number of new targeted therapies are in clinical development for specific mutational populations in mNSCLC. Even though the clinical studies are somewhat early, oncologists are beginning to take notice of these agents
  • All of these agents are seen as having better efficacy and an improved safety profile when compared to the currently available options for these subgroups of patients
  • As their clinical development continues and the results mature, oncologists will likely be quick to integrate these agents as they obtain regulatory approval and commercial availability in their countries. This will impact both the current treatments used for these patients and the testing for these specific genetic alterations (see our full report for more details around current genetic testing practices)

For a more detailed analysis report, please click here to visit MDoutlook or click here to view this report.

Submitted by: Robert Stephan, SVP, Research & Operations and Jan Heybroek, President MDoutlook.

 

 

article register

Recent Posts

Recent Comments

Archives

Categories

Post a Comment

You must be logged in to post a comment